TABLE 1.
Patients' Information
| No. | Gender/Age (year) | FAB type | AML cells in bone marrow (%) | WBC (109/L) | Hb (g/L) | PLT (109/L) | Cytogenetic profile | Mutation status |
|---|---|---|---|---|---|---|---|---|
| AML#1 | Male/51 | M5 | 72.1 | 80.08 | 56.0 | 5 | 46, XY[20] | None |
| AML#2 | Male /46 | M5 | 69.5 | 15.22 | 57.0 | 10 | 46, XY[20] | None |
| AML#3 | Female /48 | M5 | 95.3 | 71.38 | 51.0 | 18 | 46, XX[20] | CEBPA |
| AML#4 | Male /53 | M4Eo | 66.7 | 199.4 | 61.0 | 16 | 46, XY, inv(16)(p13q22)[20]; CBFβ‐MYH11 | NRAS; TET2; ASXL1; TP53; WT1 |
| AML#5 | Male /29 | M5 | 59.6 | 283.96 | 65.0 | 13 | 46, XY; CBFβ‐MYH11 | WT1 |
| AML#6 | Male /17 | M5 | 47.8 | 139.89 | 50.0 | 54 | 46, XY[20] | None |
| AML#7 | Female /72 | M2 | 87.5 | 48.21 | 51.0 | 37 | 46, XX[20] | TP53 |
| AML#8 | Female /50 | M5 | 95.1 | 6.71 | 117.0 | 55 | 46, XX[20]; FLT3‐ITD | CEBPA; GATA2; IDH2; WT1; TET2 |
| AML#9 | Female /48 | M5 | 89.7 | 206.81 | 56.0 | 37 | 46, XX[20]; MLL‐PTD | None |
| AML#10 | Male /55 | M5 | 27.2 | 183.58 | 47.0 | 42 | 46, XY[20]; FLT3‐ITD | None |
WBC, white blood cell; HB, hemoglobin; PLT, platelet.